Peter Gibson
Appearances
- DateMay 8, 2023BACKGROUND: The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST) pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes following in-utero exposure require elucidation…
- DateMay 8, 2023BACKGROUND: Irritable bowel syndrome (IBS) is a common disorder with complex pathophysiological mechanisms. Prior studies suggest that 25-50% of patients with diarrhea-predominant IBS (IBS-D) have evidence of bile acid (BA) diarrhea (BAD)…
Presenter
Speakers
- DateMay 20, 2024Gastrointestinal (GI) symptoms are common in endometriosis, affecting >75% of sufferers. These symptoms overlap with numerous GI disorders, most notably irritable bowel syndrome (IBS). Common pathophysiological mechanisms such as visceral hypersensitivity might explain this overlap…
- DateMay 18, 2024Irritable bowel syndrome (IBS) is the most common disorder of gut-brain interaction with a worldwide prevalence of approx. 11%. Gut-directed hypnotherapy (GDH) is an effective IBS-targeted therapy, but with limited accessibility…
Presenter